Cerevel Therapeutics, LLC clinical trials

Acquired by AbbVie, Aug 1, 2024 · source ↗

The registry lists 22 studies whose lead sponsor is Cerevel Therapeutics, LLC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 14, 2025.

Studies

Recruiting first, then most recently updated. Showing 22 of 22. All AbbVie studies →

• Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral DosingCompletedNCT05547542Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy ParticipantsCompletedNCT05138653Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male ParticipantsCompletedNCT06435923Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult ParticipantsCompletedNCT06366243Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male ParticipantsCompletedNCT06301971Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult ParticipantsCompletedNCT05965219Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal FunctionCompletedNCT05404542Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's DiseaseCompletedNCT05610189Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult ParticipantsCompletedNCT05915546Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult ParticipantsCompletedNCT05933187Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult ParticipantsCompletedNCT05824143Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral DosingCompletedNCT04787302Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic FunctionCompletedNCT05404529Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult ParticipantsCompletedNCT05581823Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With SchizophreniaCompletedNCT05245539Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy ParticipantsCompletedNCT05106309Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy ParticipantsCompletedNCT05123079Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy SubjectsCompletedNCT04592536Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• A 2-Part Trial of CVL-751 in Subjects With Parkinson's DiseaseCompletedNCT04295642Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• A Multiple Ascending Dose Trial of CVL-231 in Subjects With SchizophreniaCompletedNCT04136873Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy SubjectsCompletedNCT04241393Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie

• A Single Ascending Dose Trial of CVL-936 in Healthy SubjectsTerminatedNCT04232878Phase 1

  Sponsor listed in the registry: Cerevel Therapeutics, LLC · First submitted before Cerevel Therapeutics, LLC became part of AbbVie